Lugano, June 18-22, 2019
Total Page:16
File Type:pdf, Size:1020Kb
NEWSLETTER FÜR ONKOLOGIE UND ONKOLOGISCHE HÄMATOLOGIE · www.oncoletter.ch Bild Thomas Ferber© Lugano, Via Canova: Blick über die Riva Giocondo Albertolli auf den Luganersee MORE TOPICS 15th International Conference on Malignant Lymphoma (ICML) - Lugano, June 18-22, 2019 4th Zurich Immuno- Oncology Symposium ICML ist gemäss Michael Hallek, Köln, eine wirklich spezielle Konferenz, 22nd August, 2019, Zurich, Switzerland die in den letzten 38 Jahren zusammen mit der heutigen 15 Mal stattfand. Webcasts page 6 Bedeutsam ist für Hallek auch, dass die gesamte Community an dieser Konferenz teilnimmt. Oncoletter hat die wichtigsten Links zu den Abs- WCGIC 2019 tracts zusammengestellt. Und gibt abschliessend noch eine kurze Zu- July 3-6, 2019, Barcelona, Spain sammenfassung zu den Sessions «MULTIPLE MYELOMA: EVERY YEAR A Webcasts page 7 NEW STANDARD?» und «HOW TO APPROACH CLL IN CLINICAL PRACTICE» 2nd Zurich Lung Cancer Continue on page 2 Symposium July 5, 2019, Zurich, Switzerland 22. August 2019: 4th Zurich Webcasts page 9 Immuno-Oncology Symposium EHA June 13-16, 2019, Amsterdam, Oncoletter wurde vom Comprehen- Netherland sive Cancer Center Zurich beauf- Webcasts page 12 tragt, das 4. Zürcher Immun-Onko- logie Symposium aufzuzeichnen. ASCO Wer nicht teilnehmen konnte, hat May 31-June 4, 2019, Chicago, USA über die bereitgestellten Links die Webcasts page 15 Möglichkeit, die Vorträge jetzt zu verfolgen. Congress Calendar page 20 Continue on page 6 2 NEWSLETTER FÜR ONKOLOGIE UND ONKOLOGISCHE HÄMATOLOGIE · www.oncoletter.ch Continued: ICML 2019 PLENARY SESSION C. Rushton, M. Alcaide, M. Cheung, N. Abstracts Conclusion: Overall, the this phase II study improved PFS in Thomas, et al. ROBUST study did not meet the primary newly diagnosed DLBCL. endpoint of PFS for R2CHOP vs placebo/ LINK TO ABSTRACT IDENTIFYING MUTATIONS ENRICHED R-CHOP in previously untreated patients IN RELAPSED‐REFRACTORY DLBCL TO with ABC‐DLBCL, although a positive DERIVE GENETIC FACTORS UNDERLY- trend favoring R2CHOP has been ING TREATMENT RESISTANCE observed in advanced stage and higher risk patients. The safety profile of P. Langerbeins, J. Bahlo, C. Rhein, H. Abstracts Conclusion: DLBCL patients R2CHOP was consistent with those of Gerwin, et al. with mutations in relapse‐enriched individual medicines, and no new safety genes are at a higher risk of treatment signals were identified with the combi- IBRUTINIB VERSUS PLACEBO IN failure. Mutations in these genes, nation. PATIENTS WITH ASYMPTOMATIC, specifically hotspot deletions, may have LINK TO ABSTRACT TREATMENT‐NAÏVE EARLY STAGE CLL: power as biomarkers to identify patients PRIMARY ENDPOINT RESULTS OF THE at a high risk of relapse and could PHASE 3 DOUBLE‐BLIND RANDO- inform on the mechanism of acquired MIZED CLL12 TRIAL resistance to components of R‐CHOP. LINK TO ABSTRACT G.S. Nowakowski, F. Hong, D.W. Scot,t Abstracts Conclusion: The results of R. Macon, et al. this study allow to conclude that ibrutinib significantly improves EFS, PFS ADDITION OF LENALIDOMIDE TO and TTNT in patients with treatment‐ R-CHOP (R2CHOP) IMPROVES OUTCO- naïve early stage CLL when compared to U. Vitolo, T.E. Witzig, R.D. Gascoyne, MES IN NEWLY DIAGNOSED DIFFUSE placebo. There were no significant D.W. Scott, et al. LARGE B‐CELL LYMPHOMA (DLBCL): differences in adverse events between FIRST REPORT OF ECOG‐ACRIN1412 A both study arms. ROBUST: First report of phase III RANDOMIZED PHASE 2 US INTER- LINK TO ABSTRACT randomized study of lenalidomide/R‐ GROUP STUDY OF R2CHOP VS R‐CHOP CHOP (R2CHOP) vs placebo/R-CHOP in previously untreated ABC‐type diffuse Abstracts Conclusion: The addition of large BCcell lymphoma lenalidomide to R-CHOP (R2CHOP) in Abstracts from ICML 2019 presentations Introductory Press Conference MANTLE CELL LYMPHOMA NON-CLINICAL AND EARLY CLINICAL Step forward in aggressive lymphoma DATA WITH NEW COMBINATIONS Dr. Grzegorz Nowakowski PET IMAGING Step forward in chronic lymphocytic HIGH RISK LARGE B-CELL LYMPHOMAS leukemia treatment PEDIATRIC LYMPHOMA Prof. Dr. Michael Hallek HODGKIN LYMPHOMA Gene therapy of lymphomas and RESULTS FROM SINGLE AGENT TRIALS Liquid Biopsy FOLLICULAR LYMPHOMA Prof. Dr. Davide Rossi ONGOING TRIALS EXTRANODAL LYMPHOMAS DLBCL: CLINICAL DATA NEW DATA ON T-CELL AND OTHER CLL LYMPHOMAS TREATMENT WITH NOVEL ANTIBODIES ADVANCES IN CAR T-CELL TREATMENT T-CELL LYMPHOMAS NEW DRUG COMBINATIONS CLL AND MORE INDOLENT NON-FOLLICULAR LYMPHOMA LYMPHOMA PATHOLOGY CHEMOTHERAPY-FREE STRATEGIES Continue on page 3 3 NEWSLETTER FÜR ONKOLOGIE UND ONKOLOGISCHE HÄMATOLOGIE · www.oncoletter.ch Continued: ICML 2019 Continue on page 4 4 NEWSLETTER FÜR ONKOLOGIE UND ONKOLOGISCHE HÄMATOLOGIE · www.oncoletter.ch Continued: ICML 2019 Continue on page 6 Oncoletter wird von der Nationalen Strategie gegen Krebs (NSK) seit Februar 2016 als federführende Organisation auf ihrer Homepage aufgeführt. 6 NEWSLETTER FÜR ONKOLOGIE UND ONKOLOGISCHE HÄMATOLOGIE · www.oncoletter.ch Continued: ICML 2019 HOW TO APPROACH CLL IN CLINICAL PRACTICE Michael Hallek, Universität zu Köln (Summary from slides presented: Treatment algorithm) CLL first line treatment (updated June 2019) Stage Del(17p) Fitness IGVH Therapy or p53mut Binet A-B, Rai =- Irrelevant Irrelevant Irrelevant None II, inactive disease Active disease or Yes Irrelevant Irrelevant Ibrutinib or Venetoclax + Obinutuzumab or Idelalisib Binet C or Rai + III-IV Rituximab (if contraindications for Ibrutinib)* No Go go M FCR (BR above 65 years) or Ibrutinib* U Ibrutinib or FCR (BR above 65 years)* Slow go M Venetoclax + Obinutuzumab or Chlorambucil + Obinutuzumab or Ibrutinib* U Venetoclax + Obinutuzumab or Ibrutinib or Chlorambucil + Obinutuzumab* * Consider and discuss with patient: long-term vs fixed (6-12m) duration therapy, lack of convincing evidence of overall survival differences, specific side effects of each therapeutic option (myelosuppression, infections, secondary malignancies for CIT; cardiac toxicity, bleeding and autoimmune disease for Ibru; TLS and infections for Ven-Obi; autoimmune disease (diarrhea) and opportunistic infections for Idelalisib). CLL 2nd line treatment 2019 Response to 1st line therapy Fitness Therapy Refractory or progress within 3 years Go go Change to one of the following options: Ibrutinib, Idelalisib + R, Venetoclax + Rituximab, FA, FCR (after BR), Venetoclax, A- Dex, Lenalidomide (+R), BR (after FCR). Discuss consolidation with allogeneic SCT. Slow go Change to one of the following options: Ibrutinib, Idelalisib + R, Venetoclax (+ Rituximab), A, FCR-lite, BR, Lenalidomide (+R), Ofatumumab, HD R. Progress after 3 years All Repetition of 1st line therapy is possible 4th Zurich Immuno-Oncology Symposium 2019 Dear colleagues PROGRAMM Immune Checkpoint Inhibition: Patrick Roth We invite you to take part in the 4th Therapeutic Developments I Challenges in Optimizing Treatment Zürich Immuno-Oncology Symposium Melanoma: Bart Neyns; Combining Immune Checkpoint Inhibition recorded by ONCOLETTER & organized Chest Tumors: Rolf Stahel; with Targeted Therapy: Ross Soo; by the Comprehensive Cancer Center Head and Neck Cancer: Kevin Harrington Combining Immune Checkpoint Inhibition Zürich where a panel of renowned with Radiotherapy: Matthias Guckenberger; national and international experts will Therapeutic Developments II Moving Beyond PD-L1 / PD1 Targeting: Stefan Zimmermann provide you with an overview of the CNS Tumor: Michael Weller; Genitourinary Malignancies: Lewis Au; field. Hemato-Oncology: Markus Manz Cell-based Therapies TIL-Cells: John Haanen; Prof. Dr. Rolf Stahel, Chair Challenges in Patient Management Car-T-Cells: Hermann Einsele Comprehensive Cancer Center Zürich The Issue of Steroid Use with Immune Checkpoint Inhibition: Alessandra Curioni; Keynote Address Prof. Dr. Michael Weller, Directorate Microbiome, Proton Pump Inhibitors and Single Cell Screening in Precision Medici- Comprehensive Cancer Center Zürich Management of Gastrointestinal Toxicity: ne: Burkhard Becher Lisa Derosa; Immune related Neurological Toxicity of Link to Presentations 7 NEWSLETTER FÜR ONKOLOGIE UND ONKOLOGISCHE HÄMATOLOGIE · www.oncoletter.ch ESMO 21st World Congress on Gastrointestinal Cancer (WCGIC) July 3-6, 2019 - Barcelona According to the organizers, the ESMO 21st World Congress on Gastrointestinal Cancer represents the year’s most important gathering designed to focus on reversing the current global statistics that rank gastrointestinal malignancies as the leading causes of cancer deaths worldwide. Oncoletter is providing you with the most important news from the conference and with useful links to more information on the conference website such as abstracts and session links. Choice of important papers presented at the daily WCGIC press conferences Wednesday, 3 July, Opening Press Conference: Pancreatic Cancer is rising for unknown reasons; Patients living with metastatic colorectal cancer: what are their most pressing needs? An international survey (Abstract PD-023); ESMO World GI Cancer 2019: what to look out for: Thursday, 4 July: Continue on page 8 8 NEWSLETTER FÜR ONKOLOGIE UND ONKOLOGISCHE HÄMATOLOGIE · www.oncoletter.ch Continued: ESMO 21st WCGIC Friday, 5 July: Comments on TAGS by Eric Van Cutsem, Josep Tabernero and Julien Taieb Continue on page 9 9 NEWSLETTER FÜR ONKOLOGIE UND ONKOLOGISCHE HÄMATOLOGIE · www.oncoletter.ch Continued: ESMO 21st WCGIC Statement Julien Taieb: See also statements by Gerald Prager, Vienna, on two studies (APACT & POLO) and on treatment options for pancreatic cancer presented at the ESMO-GI: Do you remember this sight? If not, check